Interview 7 Feb 2018
Hookipa CEO “Sleeps Quite Well at Night” with €50M Cash Pile and Cancer Vaccine Progress
…company is to exploit its technology platform to produce modulatory vectors that can be used with different antigens to reduce time to market and regulatory efforts. The ten-year plan is…